Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;3(6):1097-104.

Review of tenofovir-emtricitabine

Saba Woldemichael Masho  1 , Cun-Lin Wang, Daniel E Nixon
Affiliations

Review of tenofovir-emtricitabine

Saba Woldemichael Masho et al. Ther Clin Risk Manag. 2007 Dec.

Abstract

Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality. Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience are being utilized. Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fixed-dose combinations. In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clinical trials, one-pill-a-day dosing convenience, and relatively low toxicity. In addition, the drug is active against hepatitis B virus. Caution must be exercised in patients with renal insufficiency, or when the drug is used with certain other drugs. This manuscript reviews the use of TDF-FTC in the treatment of HIV.

Keywords: FTC; TDF; Truvada; antiretroviral agent; emtricitabine; tenofovir.

PubMed Disclaimer

References

    1. Barrios A, Gracia-Benayas T, Gonzalez-Lahoz J, et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18:960–3. - PubMed
    1. Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS. 2005;19:1722–3. AIDS, 19:569–75 Comment in. - PubMed
    1. Bartlett JG, Gallant JE. 2005–2006 Medical management of HIV infection. Johns Hopkins Medicine. Health Publishing Business Group. 2005
    1. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol. 2006;44(1 Suppl):S90–4. - PubMed
    1. Benhamou Y, Tubia R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. New Engl J Med. 2003;348:177–8. - PubMed

LinkOut - more resources